LSD1-IN-17

LSD1-IN-17

• UNSPSC Description: LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 17.2 μM[1].
• Target Antigen: Histone Demethylase; Monoamine Oxidase
• Type: Reference compound
• Related Pathways: Epigenetics;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/lsd1-in-17.html
• Solubility: 10 mM in DMSO
• Smiles: NC1CC1C2=CC=C(C=C2)NC(C3=CC=CC(C4=CSC=C4)=C3)=O
• Molecular Weight: 334.43
• References & Citations: [1]Fioravanti R, et al. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. J Enzyme Inhib Med Chem. 2022 Dec;37(1):973-985.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported